EP1156826B1
(en)
|
1999-02-25 |
2009-05-27 |
National Jewish Center For Immunology And Respiratory Medicine |
Product and method for treatment of conditions associated with receptor-desensitization
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060177439A1
(en)
*
|
2004-12-15 |
2006-08-10 |
Scott Koenig |
FcgammaRIIB-specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7425619B2
(en)
|
2002-08-14 |
2008-09-16 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20090017023A1
(en)
*
|
2002-08-14 |
2009-01-15 |
Macrogenics, Inc. |
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
US7763256B2
(en)
|
2002-12-23 |
2010-07-27 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
|
US8012472B2
(en)
|
2002-12-23 |
2011-09-06 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocytes
|
WO2007094776A1
(en)
*
|
2006-02-15 |
2007-08-23 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocyte differentiation
|
WO2004059318A2
(en)
|
2002-12-23 |
2004-07-15 |
William Marsh Rice University |
Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7355008B2
(en)
*
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
CA2512974A1
(en)
*
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
Soluble fc.gamma.r fusion proteins and methods of use thereof
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1648507B1
(en)
|
2003-07-24 |
2017-01-25 |
Innate Pharma S.A. |
Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US20050208095A1
(en)
*
|
2003-11-20 |
2005-09-22 |
Angiotech International Ag |
Polymer compositions and methods for their use
|
CA2547126C
(en)
*
|
2003-11-26 |
2014-07-15 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Substance binding human igg fc receptor iib (fcyriib)
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
EP2053062A1
(en)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
SG173322A1
(en)
*
|
2004-04-16 |
2011-08-29 |
Macrogenics Inc Dw Us |
Fc gammad riib - specific antibodies and methods of use thereof
|
WO2005110474A2
(en)
*
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
EP2213683B1
(en)
|
2004-08-04 |
2013-06-05 |
Mentrik Biotech, LLC |
Variant Fc regions
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
WO2006028956A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Anti-fc-gamma riib receptor antibody and uses therefor
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
JP2008516586A
(ja)
*
|
2004-09-30 |
2008-05-22 |
メダレックス インコーポレーティッド |
Fcγ受容体II(CD32)に対するヒトモノクローナル抗体
|
WO2006043615A1
(ja)
|
2004-10-21 |
2006-04-27 |
Ono Pharmaceutical Co., Ltd. |
免疫抑制受容体の用途
|
AU2005335714B2
(en)
*
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP1817340B1
(en)
*
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
EP1674479A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
EP1835935A4
(en)
*
|
2004-12-30 |
2009-06-17 |
Univ Rockefeller |
COMPOSITIONS AND METHODS FOR IMPROVED DENDRITIC CELL REPRODUCTION AND FUNCTION
|
US20060275282A1
(en)
*
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
KR101335798B1
(ko)
|
2005-02-15 |
2013-12-02 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US8173608B2
(en)
*
|
2005-03-04 |
2012-05-08 |
Riken |
Compound having cyclic structure and use thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP5838021B2
(ja)
*
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
DK1874821T3
(da)
|
2005-04-26 |
2013-07-08 |
Trion Pharma Gmbh |
Kombination af antistoffer med glykokortikoider til behandling af kræft
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
US8309690B2
(en)
|
2005-07-01 |
2012-11-13 |
Medimmune, Llc |
Integrated approach for generating multidomain protein therapeutics
|
MX2008000379A
(es)
*
|
2005-07-07 |
2008-03-18 |
Coley Pharm Group Inc |
Anticuerpo anti-citla-1 y terapia de combinacio con oligodesoxinucleotido sintetico que contiene motivo cpg.
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
ES2526811T3
(es)
*
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
TWI615407B
(zh)
*
|
2005-08-26 |
2018-02-21 |
羅齊克雷雅公司 |
具有經改變細胞傳訊活性之改質抗原結合分子
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
AU2006304387A1
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Llc |
Cell display of antibody libraries
|
EP1801234A1
(en)
*
|
2005-12-22 |
2007-06-27 |
Stichting Sanquin Bloedvoorziening |
Diagnostic methods involving determining gene copy numbers and use thereof
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2007106707A2
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
EP1870422A1
(en)
*
|
2006-06-20 |
2007-12-26 |
SuppreMol GmbH |
Means for the treatment of diseases characterized by an excessive immune reaction
|
EP2032159B1
(en)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
ES2599319T3
(es)
*
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
AU2007285976B2
(en)
*
|
2006-08-14 |
2011-08-18 |
Xencor, Inc |
Optimized antibodies that target CD19
|
MX2009002414A
(es)
|
2006-09-08 |
2009-05-20 |
Medimmune Llc |
Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
|
CA2664333A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Memorial Sloan Kettering Cancer Center |
Methods of diagnosing, treating, or preventing plasma cell disorders
|
EP2064240A2
(en)
*
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008070117A1
(en)
|
2006-12-04 |
2008-06-12 |
Promedior, Inc. |
Conjoint therapy for treating fibrotic diseases
|
WO2008140603A2
(en)
*
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
EP2737907A3
(en)
|
2007-05-07 |
2014-11-05 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
NO3072525T3
(xx)
|
2007-05-14 |
2018-06-30 |
|
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
US8497243B2
(en)
|
2007-07-06 |
2013-07-30 |
Promedior, Inc. |
Methods and compositions useful in the treatment of mucositis
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
AU2008282218A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
PE20090499A1
(es)
|
2007-08-09 |
2009-05-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
AU2008289857B2
(en)
*
|
2007-08-23 |
2014-06-05 |
Phc Corporation |
Use of non-specific reaction inhibitor
|
KR101397554B1
(ko)
*
|
2007-11-09 |
2014-05-21 |
재단법인서울대학교산학협력재단 |
치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
BRPI0822099A2
(pt)
|
2007-12-21 |
2017-05-23 |
Medimmune Ltd |
membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
EP3045475B1
(en)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
DK2132228T3
(da)
|
2008-04-11 |
2011-10-10 |
Emergent Product Dev Seattle |
CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
|
EP2282770B1
(en)
*
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
CN102438652B
(zh)
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
抗体制剂
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
PT2405928T
(pt)
|
2009-03-11 |
2017-02-07 |
Promedior Inc |
Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
|
JP5980508B2
(ja)
|
2009-03-11 |
2016-08-31 |
プロメディオール, インコーポレイテッド |
自己免疫障害に対する処置方法
|
UA110323C2
(en)
|
2009-06-04 |
2015-12-25 |
Promedior Inc |
Derivative of serum amyloid p and their receipt and application
|
EP2987803B1
(en)
|
2009-06-17 |
2018-08-29 |
Promedior Inc. |
Sap variants and their use
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
US20120263701A1
(en)
|
2009-08-24 |
2012-10-18 |
Volker Schellenberger |
Coagulation factor vii compositions and methods of making and using same
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
|
CN113528485A
(zh)
|
2009-11-02 |
2021-10-22 |
华盛顿大学 |
治疗性核酸酶组合物和方法
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
SG183847A1
(en)
|
2010-03-04 |
2012-10-30 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
KR20140002601A
(ko)
|
2010-07-09 |
2014-01-08 |
바이오겐 이데크 헤모필리아 인코포레이티드 |
키메라 응고 인자
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
HUE033008T2
(hu)
|
2011-04-13 |
2017-11-28 |
Bristol Myers Squibb Co |
FC fúziós proteinek, amelyek tartalmaznak új linkereket
|
IL300276B1
(en)
|
2011-04-29 |
2024-07-01 |
Univ Washington |
Therapeutic nuclease preparations and methods
|
ES2732213T3
(es)
|
2011-05-21 |
2019-11-21 |
Macrogenics Inc |
Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
|
SG195073A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
EP3527218A1
(en)
|
2011-06-10 |
2019-08-21 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
JP2014532053A
(ja)
|
2011-09-30 |
2014-12-04 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
治療用ペプチド
|
WO2013085972A1
(en)
|
2011-12-05 |
2013-06-13 |
X-Body, Inc. |
Pdgf receptor beta binding polypeptides
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
EP2812027A1
(en)
|
2012-02-07 |
2014-12-17 |
Innate Pharma |
Mica binding agents
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
LT2814840T
(lt)
|
2012-02-15 |
2020-02-25 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
|
EP2831113B1
(en)
|
2012-03-28 |
2018-03-14 |
Sanofi |
Antibodies to bradykinin b1 receptor ligands
|
MX2014013637A
(es)
|
2012-05-07 |
2015-02-05 |
Sanofi Sa |
Metodos para prevencion de la formacion de biopelicula.
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
EP4079316A1
(en)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
WO2013185114A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
EP3404105A1
(en)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
PT2882450T
(pt)
|
2012-07-11 |
2020-02-19 |
Bioverativ Therapeutics Inc |
Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
|
US9334332B2
(en)
|
2012-07-25 |
2016-05-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
KR102426488B1
(ko)
|
2012-09-12 |
2022-07-28 |
젠자임 코포레이션 |
변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
US10669324B2
(en)
|
2012-10-30 |
2020-06-02 |
Suppremol Gmbh |
Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
|
ES2645634T3
(es)
|
2013-02-12 |
2017-12-07 |
Bristol-Myers Squibb Company |
Métodos de replegado de proteínas a elevado pH
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
DK2956482T3
(en)
|
2013-02-14 |
2017-10-16 |
Innate Pharma |
TREATMENT OF PERFECT T cell lymphoma
|
DK3889173T3
(da)
|
2013-02-15 |
2023-10-09 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
JP6360077B2
(ja)
|
2013-02-20 |
2018-07-18 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
末梢t細胞リンパ腫の処置における使用のためのkir3dl2に特異的に結合する化合物
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
RU2708314C2
(ru)
|
2013-03-11 |
2019-12-05 |
Джензим Корпорейшн |
Гипергликозилированные связывающие полипептиды
|
CN111925437A
(zh)
|
2013-03-14 |
2020-11-13 |
宏观基因有限公司 |
与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
|
CN105142668B
(zh)
|
2013-03-15 |
2018-04-27 |
达纳-法伯癌症研究院公司 |
治疗性肽
|
UY35463A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix.
|
EP2970921B1
(en)
|
2013-03-15 |
2018-09-19 |
aTyr Pharma, Inc. |
Histidyl-trna synthetase-fc conjugates
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
EP3043813B1
(en)
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
KR20160035077A
(ko)
|
2013-08-13 |
2016-03-30 |
사노피 |
플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
EP2837637A1
(en)
*
|
2013-08-16 |
2015-02-18 |
SuppreMol GmbH |
Novel anti-FcyRIIB IgG-type antibody
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
JP6705746B2
(ja)
|
2013-12-06 |
2020-06-03 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
治療用ペプチド
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
LT3087095T
(lt)
|
2013-12-24 |
2019-09-10 |
Argenx Bvba |
Fcrn-antagonistai ir naudojimo būdai
|
DK4176894T3
(da)
|
2014-01-10 |
2024-05-27 |
Bioverativ Therapeutics Inc |
Kimære faktor viii-proteiner og anvendelser deraf
|
WO2015136052A1
(en)
|
2014-03-14 |
2015-09-17 |
Innate Pharma |
Humanized antibodies with increased stability
|
EP3925973A1
(en)
|
2014-03-14 |
2021-12-22 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
SG10201808158UA
(en)
|
2014-03-19 |
2018-10-30 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
KR102399028B1
(ko)
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
이중-특이적 항원-결합 폴리펩티드
|
GB2526139A
(en)
*
|
2014-05-15 |
2015-11-18 |
Biolnvent Internat Ab |
Medicaments, uses and methods
|
BR112016028378A2
(pt)
|
2014-06-06 |
2017-10-24 |
Bristol Myers Squibb Co |
anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
|
CA2952727A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific nkp46 binding proteins
|
JP6702893B2
(ja)
|
2014-06-27 |
2020-06-03 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
多重特異的抗原結合タンパク質
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
KR102424169B1
(ko)
|
2014-08-13 |
2022-07-25 |
수프레몰 게엠베하 |
Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
AU2015323769A1
(en)
|
2014-09-26 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Stabilized adrenomedullin derivatives and use thereof
|
MX2017004076A
(es)
|
2014-09-29 |
2017-07-04 |
Univ Duke |
Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
|
PL3204425T3
(pl)
|
2014-10-09 |
2021-03-08 |
Genzyme Corporation |
Glikomodyfikowane koniugaty przeciwciał z lekami
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
KR102598068B1
(ko)
|
2014-10-23 |
2023-11-06 |
이나뜨 파르마 에스.에이. |
항-nkg2a 제제를 이용하는 암 치료
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
TWI758928B
(zh)
|
2014-11-21 |
2022-03-21 |
美商必治妥美雅史谷比公司 |
抗cd73抗體及其用途
|
PL3221346T3
(pl)
|
2014-11-21 |
2021-03-08 |
Bristol-Myers Squibb Company |
Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
PL3268391T3
(pl)
|
2015-03-09 |
2022-01-03 |
Argenx Bvba |
Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ox40に対する抗体およびその使用
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
AU2016284866B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
CA2990518A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
PT3411478T
(pt)
|
2016-02-01 |
2022-09-13 |
Bioverativ Therapeutics Inc |
Genes do fator viii otimizados
|
JP2019517991A
(ja)
|
2016-03-01 |
2019-06-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
低減したadcpを有するオビヌツズマブ及びリツキシマブ変異体
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
CN108779178A
(zh)
|
2016-03-15 |
2018-11-09 |
依奈特制药公司 |
抗mica抗体
|
JP2019518713A
(ja)
|
2016-03-16 |
2019-07-04 |
メリマック ファーマシューティカルズ インコーポレーティッド |
癌療法のための改変trail
|
EP3442574A4
(en)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
|
EA039084B1
(ru)
|
2016-05-09 |
2021-12-01 |
Бристол-Майерс Сквибб Компани |
Антитела к tl1a и их применения
|
JP7148504B2
(ja)
|
2016-06-08 |
2022-10-05 |
ゼンコー,インコーポレイティド |
CD32Bに交差結合した抗CD19抗体を用いたIgG4関連疾患の治療
|
JP7308034B2
(ja)
|
2016-07-01 |
2023-07-13 |
リゾルブ セラピューティクス, エルエルシー |
最適化二重ヌクレアーゼ融合物および方法
|
UY37325A
(es)
|
2016-07-14 |
2018-01-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
WO2018073363A1
(en)
|
2016-10-21 |
2018-04-26 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
US20230192896A1
(en)
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
EP3548066A1
(en)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
BR112019011198A2
(pt)
|
2016-12-02 |
2019-12-17 |
Bioverativ Therapeutics Inc |
métodos de indução de tolerância imune a fatores de coagulação
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CN110462027A
(zh)
|
2017-01-06 |
2019-11-15 |
艾欧凡斯生物治疗公司 |
用肿瘤坏死因子受体超家族(tnfrsf)激动剂扩增肿瘤浸润淋巴细胞(til)及til和tnfrsf激动剂的治疗组合
|
EP3565586A1
(en)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
KR102573778B1
(ko)
|
2017-02-17 |
2023-08-31 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시뉴클레인에 대한 항체 및 그의 용도
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
WO2018195338A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
EP3625251A1
(en)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
WO2018218056A1
(en)
|
2017-05-25 |
2018-11-29 |
Birstol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
SG11202000764RA
(en)
|
2017-08-09 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
CN111315767A
(zh)
|
2017-08-22 |
2020-06-19 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
CA3079363A1
(en)
|
2017-11-21 |
2019-05-31 |
Innate Pharma |
Multispecific antigen binding proteins
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
BR112020011483A2
(pt)
|
2017-12-08 |
2020-11-24 |
Argenx Bvba |
uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
BR112020015228A2
(pt)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
Uso de vetores lentivirais que expressam fator viii
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
CN111971304A
(zh)
|
2018-03-21 |
2020-11-20 |
戊瑞治疗有限公司 |
在酸性pH结合至VISTA的抗体
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
TW202003551A
(zh)
|
2018-03-28 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
JP2021519594A
(ja)
|
2018-04-02 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗trem−1抗体およびその使用
|
JP7402541B2
(ja)
|
2018-05-03 |
2023-12-21 |
ユニバーシティ オブ ロチェスター |
抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
|
AU2019270184A1
(en)
|
2018-05-18 |
2020-11-26 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia A
|
WO2019236417A1
(en)
|
2018-06-04 |
2019-12-12 |
Biogen Ma Inc. |
Anti-vla-4 antibodies having reduced effector function
|
CN114903978A
(zh)
|
2018-07-03 |
2022-08-16 |
百时美施贵宝公司 |
Fgf-21配制品
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
MX2021001599A
(es)
|
2018-08-09 |
2021-07-02 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y sus usos para la terapia genica no viral.
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
CA3118634A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
BR112021013096A2
(pt)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
Tratamento de doença de sjögren com proteínas de fusão de nuclease
|
BR112021014106A2
(pt)
|
2019-01-22 |
2021-10-13 |
Bristol-Myers Squibb Company |
Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
|
AU2020210710A1
(en)
|
2019-01-22 |
2021-07-29 |
Innate Pharma |
Treatment of T cell lymphoma
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
CA3138072A1
(en)
|
2019-06-07 |
2020-12-10 |
Argenx Bvba |
Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
|
CN114174326A
(zh)
|
2019-06-18 |
2022-03-11 |
拜耳公司 |
长期稳定的肾上腺髓质素类似物及其用途
|
JP2022540904A
(ja)
|
2019-07-15 |
2022-09-20 |
ブリストル-マイヤーズ スクイブ カンパニー |
ヒトtrem-1に対する抗体およびその使用
|
WO2021011678A1
(en)
|
2019-07-15 |
2021-01-21 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
KR20220065816A
(ko)
|
2019-09-19 |
2022-05-20 |
브리스톨-마이어스 스큅 컴퍼니 |
산성 pH에서 VISTA에 결합하는 항체
|
CA3152600A1
(en)
|
2019-09-30 |
2021-04-08 |
Andrew KROETSCH |
Lentiviral vector formulations
|
CA3163172A1
(en)
|
2020-01-08 |
2021-07-15 |
Peter Verheesen |
Methods for treating pemphigus disorders
|
EP4100426A1
(en)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
AU2021225962A1
(en)
|
2020-02-28 |
2022-10-20 |
Genzyme Corporation |
Modified binding polypeptides for optimized drug conjugation
|
JP2023519930A
(ja)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
インフルエンザh3n2ウイルスのヘマグルチニン(ha)およびノイラミニダーゼ(na)に対するモノクローナル抗体
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
JP2023523480A
(ja)
|
2020-04-28 |
2023-06-06 |
ザ ロックフェラー ユニバーシティー |
中和抗sars-cov-2抗体およびその使用方法
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
TW202242085A
(zh)
|
2020-12-31 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
供自動生產腫瘤浸潤淋巴球的裝置和方法
|
EP4277926A1
(en)
|
2021-01-15 |
2023-11-22 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
TW202300014A
(zh)
|
2021-03-05 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
腫瘤儲存及細胞培養組成物
|
CA3212439A1
(en)
|
2021-03-19 |
2022-09-22 |
Michelle SIMPSON-ABELSON |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
TW202305360A
(zh)
|
2021-03-25 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
用於t細胞共培養效力測定及配合細胞療法產品使用的方法及組合物
|
BR112023019138A2
(pt)
|
2021-03-26 |
2023-10-24 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CA3219148A1
(en)
|
2021-05-17 |
2022-11-24 |
Frederick G. Vogt |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
EP4352098A1
(en)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
BR112023025476A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína de ligação multimérica e seu método de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de expressão, célula isolada e proteína de ligação para uso
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
WO2023019200A1
(en)
|
2021-08-11 |
2023-02-16 |
Viela Bio, Inc. |
Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
|
AU2022343729A1
(en)
|
2021-09-09 |
2024-03-21 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023242372A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn/hsa binding molecules and methods of use
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
US12030945B2
(en)
|
2022-10-25 |
2024-07-09 |
Seismic Therapeutic, Inc. |
Variant IgG Fc polypeptides and uses thereof
|
WO2024089609A1
(en)
|
2022-10-25 |
2024-05-02 |
Ablynx N.V. |
Glycoengineered fc variant polypeptides with enhanced effector function
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024148243A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
WO2024148241A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
WO2024148240A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|